Sort
48,018 grants matching “immunotherapy”
Therapeutic immune mechanisms of daclizumab in psoriasis
$375,750Rockefeller University · R01 · FY2002 · AI
Molecular Characterization of C. neoformans Antibodies
$375,750Arturo Casadevall · Albert Einstein College Of Medicine · R37 · FY2014 · AI
CHIMERIC SHIV MODEL FOR EVALUATING HIV IMMUNOTHERAPIES
$375,750Beth Israel Deaconess Medical Center · R01 · FY2000 · HL
Tissue-Engineered Models of Lymphatic Drainage in Breast Cancer
$375,744Esak Lee · Cornell University · R01 · FY2024 · CA
EBV Specific T-cells from 3rd party donors for treatment of EBV-associated malign
$375,713Richard J O'Reilly · Sloan-Kettering Inst Can Research · R21 · FY2011 · CA
CAREER: Systems Immunology Approach to Memory T Cell Immune Engineering
$375,708Jenny Jiang · University Of Pennsylvania · · FY2021 · ENG
HSP 110 and its role in cancer therapy
$375,693John R. Subjeck · Roswell Park Cancer Institute Corp · R01 · FY2012 · CA
Development and maintenance of human glycan and phospholipid antibody repertoires
$375,672John Franklin Kearney · University Of Alabama At Birmingham · U19 · FY2021 · AI
The role of immunosuppression in the tumor microenvironment in Hispanic/Latino patients with breast cancer
$375,635Evanthia Theodosiou Roussos Torres · University Of Southern California · P20 · FY2024 · CA
UCLA Tumor Immunology Institutional Training Grant
$375,626Michael A Teitell · University Of California Los Angeles · T32 · FY2025 · CA
Ubiquitinated Proteins in Exosomes of Immune Suppressive Myeloid Cells
$375,608Catherine C. Fenselau · Univ Of Maryland, College Park · R01 · FY2014 · GM
Image-guided Interventional Combination Liver Cancer Immunotherapy
$375,601Zhuoli Zhang · Northwestern University At Chicago · R01 · FY2020 · CA
ANTIBODY-BASED THERAPY FOR METHAMPHETAMINE ABUSE
$375,591University Of Arkansas Med Scis Ltl Rock · R01 · FY2000 · DA
Origins and functions of pancreatic cancer-associated fibroblasts
$375,586Mara H. Sherman · Sloan-Kettering Inst Can Research · R01 · FY2025 · CA
Advanced development and validation of genome-scale molecular diagnostics for microsatelliteinstability using targeted molecular counting methods
$375,579Stephen J Salipante · University Of Washington · R33 · FY2019 · CA
Optofluidic Nanoplasmonic Biosensors for Next Generation Point-of-Care Immunoassays
$375,542Pengyu Chen · Auburn University At Auburn · R35 · FY2021 · GM
Optofluidic Nanoplasmonic Biosensors for Next Generation Point-of-Care Immunoassays
$375,542Pengyu Chen · Auburn University At Auburn · R35 · FY2019 · GM
Optofluidic Nanoplasmonic Biosensors for Next Generation Point-of-Care Immunoassays
$375,542Pengyu Chen · Auburn University At Auburn · R35 · FY2022 · GM
Optofluidic Nanoplasmonic Biosensors for Next Generation Point-of-Care Immunoassays
$375,542Pengyu Chen · Auburn University At Auburn · R35 · FY2020 · GM
Optofluidic Nanoplasmonic Biosensors for Next Generation Point-of-Care Immunoassays
$375,542Pengyu Chen · Auburn University At Auburn · R35 · FY2023 · GM
Developmental Funds
$375,528Suresh S Ramalingam · Emory University · P30 · FY2024 · CA
TARGETING HISTONE DEMETHYLASE KDM5B IN BREAST CANCER
$375,493Qin Yan · Yale University · R01 · FY2023 · CA
TARGETING HISTONE DEMETHYLASE KDM5B IN BREAST CANCER
$375,493Qin Yan · Yale University · R01 · FY2022 · CA
Understanding the role and clinical potential of dominant immune suppressive myeloid-cell responses in human cancer
$375,493Kurt A Schalper · Yale University · R01 · FY2022 · CA
Understanding the role and clinical potential of dominant immune suppressive myeloid-cell responses in human cancer
$375,493Kurt A Schalper · Yale University · R01 · FY2023 · CA